VERO BEACH, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage pharmaceutical company developing next-generation cancer therapies, provides updates ...

VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today ...

Processa Pharmaceuticals, Inc. has announced a licensing agreement with Intact Therapeutics for PCS12852, a novel 5-HT4 receptor agonist aimed at treating gastroparesis and gastrointestinal motility ...

Detailed price information for Processa Pharmaceuticals Inc (PCSA-Q) from The Globe and Mail including charting and trades.

Interim analysis of Phase 1B data suggests Processa’s novel chemotherapy treatment could improve safety and efficacy in more patients by individualizing the dosing regimen for each patient HANOVER, MD ...

FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU Interim analysis of the NGC-Cap Phase 1b data shows improved safety ...

The latest price target for Processa Pharmaceuticals (NASDAQ:PCSA) was reported by HC Wainwright & Co. on September 2, 2025. The analyst firm set a price target for $1.00 expecting PCSA to fall to ...

HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next ...

Hanover, MD., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (PCSA) announced today with great sadness that Virgil Thompson, Director, passed away unexpectedly on November 9, 2023.

The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.